Form 4: Coastlands Capital LP Acquires ADIL Shares

Coastlands Capital LP reports the acquisition of 25,000 shares of ADial Pharmaceuticals, Inc. common stock.

Summary

• Coastlands Capital LP, acting as an investment adviser and general partner, acquired 25,000 shares of ADial Pharmaceuticals, Inc. common stock on June 29, 2026.
• The acquisition was made at a price of $2.60 per share.
• Following this transaction, Coastlands Capital LP beneficially owns 373,322 shares of ADial Pharmaceuticals, Inc. common stock, held indirectly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard transaction of beneficial ownership without providing new financial or strategic information.

Positives

• Coastlands Capital LP has increased its beneficial ownership in ADial Pharmaceuticals, Inc., indicating confidence in the company.
• The acquisition of 25,000 shares at a specific price point suggests a strategic investment decision.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for significant changes in beneficial ownership by insiders, providing transparency to the market regarding potential shifts in confidence or strategy by major shareholders.

Stakeholder Impact

• Shareholders: The acquisition by Coastlands Capital LP may be interpreted as a positive signal of continued investment interest in ADial Pharmaceuticals, Inc.

Key Dates

Keywords

SEC Form 4, Beneficial Ownership, ADial Pharmaceuticals, ADIL, Coastlands Capital LP, Stock Acquisition, Insider Trading